[新聞] 乳癌新藥解盲不如預期 浩鼎:仍有利3期
http://www.appledaily.com.tw/realtimenews/article/new/20160221/800000/
016年02月21日14:01
生技股王、聚焦「癌症免疫療法」的新藥廠浩鼎(4174),今由董事長張念慈率公司一級
主管對外宣布,乳癌新藥OBI-822的解盲進度。
浩鼎表示,第2/3期結果雖未呈現統計顯著意義;不過在免疫抗體反應、PFS(無惡化存
活期間)以及OS(總體存活率)方面皆有正面趨勢,認為對未來全球3期臨床測試,將具
重要的意義與價值。未來也將與台灣食藥署(TFDA)討論能否依此申請藥證,且參與全球
三期臨床測試的規劃不變。
浩鼎原本計劃在今年3月底公布解盲結果,但因浩鼎欲將 OBI-822臨床結果申請參與美國
臨床腫瘤學會(ASCO)年會,因此日前經過專家會議後,決議將解盲時間提前到2月中下
旬,此舉不僅使外界對OBI-822 解盲結果抱持樂觀態度,更讓公司股價屢創新高。
張念慈強調,此次解盲結果雖沒有在統計學上達標,但在其他免疫標準有非常顯著的臨床
意義,因此有關成功與否?若從科學上、臨床上,「這是成功的解盲」;只是就法規而言
,這次結果與當初的設定不同,未來會與台灣FDA討論是否能依此申請藥證,所以就法規
上暫時不評論成功與否。
浩鼎副董事長許友恭進一步說明,傳統的雙盲測試,是採取有用藥與未用藥的患者,進行
PFS(無惡化存活期)測試比較;但是這次獲得的結果,顯示對新藥的設計上,應該針對
有用藥者的抗體反應進行分析,這也是未來公司向美國FDA申請三期測試時,所依恃的檢
驗標準。(侯良儒/台北報導)
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 123.193.57.194
※ 文章網址: https://www.ptt.cc/bbs/Bioindustry/M.1456044751.A.3B1.html
推
02/21 19:58, , 1F
02/21 19:58, 1F
→
02/21 19:58, , 2F
02/21 19:58, 2F
→
02/21 20:42, , 3F
02/21 20:42, 3F
推
02/21 21:12, , 4F
02/21 21:12, 4F
→
02/21 21:12, , 5F
02/21 21:12, 5F
推
02/21 21:50, , 6F
02/21 21:50, 6F
→
02/21 21:52, , 7F
02/21 21:52, 7F
→
02/21 21:52, , 8F
02/21 21:52, 8F
→
02/21 21:54, , 9F
02/21 21:54, 9F
推
02/21 23:03, , 10F
02/21 23:03, 10F
推
02/21 23:36, , 11F
02/21 23:36, 11F
推
02/22 00:41, , 12F
02/22 00:41, 12F
→
02/22 01:40, , 13F
02/22 01:40, 13F
推
02/22 06:02, , 14F
02/22 06:02, 14F
推
02/22 06:32, , 15F
02/22 06:32, 15F
→
02/22 06:34, , 16F
02/22 06:34, 16F
推
02/22 09:12, , 17F
02/22 09:12, 17F
→
02/22 09:12, , 18F
02/22 09:12, 18F
推
02/22 09:22, , 19F
02/22 09:22, 19F
→
02/22 09:23, , 20F
02/22 09:23, 20F
→
02/22 09:24, , 21F
02/22 09:24, 21F
→
02/22 09:48, , 22F
02/22 09:48, 22F
推
02/22 10:18, , 23F
02/22 10:18, 23F
→
02/22 10:18, , 24F
02/22 10:18, 24F
→
02/22 10:18, , 25F
02/22 10:18, 25F
→
02/22 10:18, , 26F
02/22 10:18, 26F
推
02/22 10:37, , 27F
02/22 10:37, 27F
推
02/22 10:39, , 28F
02/22 10:39, 28F
→
02/22 10:39, , 29F
02/22 10:39, 29F
推
02/22 11:04, , 30F
02/22 11:04, 30F
→
02/22 11:04, , 31F
02/22 11:04, 31F
推
02/22 11:21, , 32F
02/22 11:21, 32F
→
02/22 11:21, , 33F
02/22 11:21, 33F
→
02/22 11:21, , 34F
02/22 11:21, 34F
→
02/22 11:22, , 35F
02/22 11:22, 35F
推
02/22 11:22, , 36F
02/22 11:22, 36F
→
02/22 11:22, , 37F
02/22 11:22, 37F
→
02/22 11:22, , 38F
02/22 11:22, 38F
→
02/22 11:22, , 39F
02/22 11:22, 39F
推
02/22 11:47, , 40F
02/22 11:47, 40F
→
02/22 11:47, , 41F
02/22 11:47, 41F
推
02/22 11:52, , 42F
02/22 11:52, 42F
→
02/22 11:52, , 43F
02/22 11:52, 43F
→
02/22 11:53, , 44F
02/22 11:53, 44F
→
02/22 11:53, , 45F
02/22 11:53, 45F
→
02/22 11:53, , 46F
02/22 11:53, 46F
→
02/22 11:53, , 47F
02/22 11:53, 47F
推
02/22 11:55, , 48F
02/22 11:55, 48F
→
02/22 11:55, , 49F
02/22 11:55, 49F
→
02/22 11:55, , 50F
02/22 11:55, 50F
→
02/22 11:56, , 51F
02/22 11:56, 51F
推
02/22 12:53, , 52F
02/22 12:53, 52F
推
02/22 15:01, , 53F
02/22 15:01, 53F
→
02/22 15:01, , 54F
02/22 15:01, 54F
→
02/22 15:01, , 55F
02/22 15:01, 55F
→
02/22 15:01, , 56F
02/22 15:01, 56F
→
02/22 15:01, , 57F
02/22 15:01, 57F
→
02/22 15:01, , 58F
02/22 15:01, 58F
推
02/22 15:18, , 59F
02/22 15:18, 59F
→
02/22 15:18, , 60F
02/22 15:18, 60F
推
02/22 18:50, , 61F
02/22 18:50, 61F
→
02/22 18:50, , 62F
02/22 18:50, 62F
→
02/22 18:50, , 63F
02/22 18:50, 63F
→
02/22 18:50, , 64F
02/22 18:50, 64F
推
02/22 20:36, , 65F
02/22 20:36, 65F
→
02/22 20:36, , 66F
02/22 20:36, 66F
→
02/22 20:36, , 67F
02/22 20:36, 67F
推
02/22 21:50, , 68F
02/22 21:50, 68F
→
02/22 21:50, , 69F
02/22 21:50, 69F